FDA rejected Vanda's Tradipitant NDA, citing insufficient efficacy data from clinical trials and long-term safety concerns. Vanda must address deficiencies, conduct two new trials, and provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback